Atreca, Inc. Made Headway
Fri, Jan 12, 2024 at 07:37 PM
Atreca, Inc. (BCEL:NASDAQ) jumped higher at $0.36, representing a gain of 52.6%. On Fri, Jan 12, 2024, BCEL:NASDAQ hit a New 2-Week High of $0.36. The stock got featured on our News Catalysts scanner on Tue, Dec 26, 2023 at 12:50 PM in the 'ACQUISITION' category. From Fri, Dec 29, 2023, the stock recorded 22.22% Up Days and 20.00% Green Days
About Atreca, Inc. (BCEL:NASDAQ)
Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Top 10 Gainers:
- Applied UV Inc. (AUVI:NASDAQ), 67.11%
- Atreca, Inc. (BCEL:NASDAQ), 52.63%
- SRIVARU Holding Limited (SVMH:NASDAQ), 46.21%
- Vinco Ventures Inc. (BBIG:NASDAQ), 42.86%
- SYLA Technologies Co. Ltd. (SYT:NASDAQ), 36.1%
- Entera Bio Ltd. (ENTX:NASDAQ), 35.17%
- Nubia Brand International Corp. (NUBI:NASDAQ), 33.4%
- Cyclo Therapeutics Inc. (CYTH:NASDAQ), 30.99%
- Nuburu Inc. (BURU:NYSEMKT), 29.25%
- Elevation Oncology Inc. (ELEV:NASDAQ), 29.25%